|
||||||
 |
||||||
|
|
|
 |
|
          August 25, 2010
August 20, 2010
|
|
All prices delayed at least 15 minutes. |
|
News ReleaseBioniche Makes Four Presentations At Prestigious SIU Congress
24/09/02 Dr. Alvaro Morales, Principal Investigator for Bioniche’s Phase I/II clinical trial in refractory Carcinoma in situ (CIS) of the bladder, showed results indicating that of the 25 enrolled patients, 24% were alive and disease free (complete response) after 18 months, and 8% showed a partial response for a total positive response rate of 32%. MCC (Urocidin™) was extremely well tolerated by the patients and there were no apparent safety concerns. The Company’s Senior Vice-President, Scientific Affairs and Chief Scientific Officer, Dr. Nigel Phillips, presented data that demonstrated MCC is effective in causing cell cycle arrest and inducing apoptosis in a range of bladder cancer cell lines derived from high grade bladder cancers and where the cells possess mutations in cell cycle/apoptosis regulators. Dr. Phillips also presented data showing that MCC (Urocidin™) stimulates urinary apoptosis markers and cytokines following intravesical administration to patients with Carcinoma in situ of the bladder. “Building on the positive clinical results obtained to date for the treatment of Carcinoma in situ of the bladder, these findings indicate MCC may be effective in treating other types of aggressive bladder cancer, such as high-grade transitional cell carcinoma,” said Dr. Phillips. “Dr. Phillips’ data is providing strong evidence that MCC’s (Urocidin™) has a therapeutic potential in high grade transitional cell carcinomas of the bladder, including refractory CIS.” added Dr. Marc Rivière. “High-grade transitional cell carcinomas, tested in vitro by Bioniche’s scientific team, account for a third of superficial bladder cancers, or approximately 40,000 new cases per year in North America and Europe. The excellent tolerability of MCC (Urocidin™) and the promising 18-month results presented by Dr. Morales provide a solid basis for Bioniche’s clinical program in bladder cancer” Dr. Mario Filion, Bioniche’s Head of Biomedical Research, presented data demonstrating that the combination of MCC with hyaluronic acid (HA) enhances both the apoptosis-inducing activity of MCC against prostate cancer cell lines, and the immune stimulatory activity of MCC (stimulation of anticancer cytokine synthesis by human immune effector cells). “These data are confirming the therapeutic potential of MCC in different urology-oncology indications. We will be reporting on Phase I safety results using an MCC/HA suspension in prostate cancer patients before the end of the year,” concluded Dr. Marc Rivière. “We have also begun to aggressively identify other oncology indications for this integrated technology”. About Bioniche Life Sciences Inc. Bioniche Life Sciences Inc. is a leading Canadian biopharmaceutical company that develops, manufactures, and markets proprietary products for human and animal health markets worldwide. The company is developing a pipeline of anti-cancer therapies based on its proprietary mycobacterial cell wall technologies. The Company has 230 employees worldwide in four business units: Bioniche Pharma, Bioniche Therapeutics, Bioniche Animal Health, and Bioniche Food Safety. For more information visit www.bioniche.com. Bioniche Life Sciences Inc. trades on the Toronto Stock Exchange (TSX) under the symbol “BNC” and currently has 27,818,445 shares outstanding. Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
|
|
Categories:
|
Copyright 2004, Bioniche Life Sciences Inc. All rights reserved | Legal Disclaimer | Privacy Policy